{"text": ["Lilly's", "Olumiant", "Meets", "Primary", "Endpoint", "in", "3rd", "Eczema", "Study"], "created_at": "2019-08-26 16:47:50"}
{"text": ["Lilly's", "Olumiant", "Meets", "Primary", "Endpoint", "in", "3rd", "Eczema", "Study"], "created_at": "2019-08-26 16:47:50"}
{"text": ["Lilly's", "Olumiant", "Meets", "Primary", "Endpoint", "in", "3rd", "Eczema", "Study"], "created_at": "2019-08-26 14:30:02"}
{"text": ["Lilly", "Receives", "U.S.", "FDA", "Approval", "for", "Taltz\u00ae", "(ixekizumab)", "for", "the", "Treatment", "of", "Active", "Ankylosing", "Spondylitis", "(Radiographic", "Axial", "Spondyloarthritis)"], "created_at": "2019-08-26 10:45:00"}
